Active Drug Surveillance Program of Ferriprox Use

CompletedOBSERVATIONAL
Enrollment

294

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Transfusional Iron Overload
Trial Locations (14)

Unknown

Thalassemia Center of North Cyprus Turkish Republic (KKTC), Nicosia

Hematology Unit, Mansoura University Children Hospital, Al Mansurah

Hematology Unit, El-Shatby Children Hospital, Alexandria University, Alexandria

Hematology Unit, Assiut University Hospital, Asyut

Ain Shams University, Cairo

Tanta University Hospital, Tanta

Hematology/Oncology Unit ; Zagazig University Children Hospital, Zagazig

Zagazig University; Thalassemia Association, Zagazig

Department of Child Health, College of Medicine and Health Sciences, Sultan Qaboos University Hospital, Muscat

King Abdulaziz University Hospital (KAAUH), Jeddah

Maternity and Children's Hospital, Maddinah

Çukurova Üniversitesi Tip Fakültesi, Çocuk Hematolojie Bilim Dali, Adana

Akdeniz Üniversitesi Hastanesi, Çocuk Sağliği, Hematolojie Kliniği, Antalya

Ïstanbul Üniversitesi Tip. Fak. Hastanesi, Çocuk Sağliği, Hematolojie Kliniği, Istanbul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT01838291 - Active Drug Surveillance Program of Ferriprox Use | Biotech Hunter | Biotech Hunter